Literature DB >> 10679640

Adrenocortical carcinoma: clinical and laboratory observations.

B L Wajchenberg1, M A Albergaria Pereira, B B Medonca, A C Latronico, P Campos Carneiro, V A Alves, M C Zerbini, B Liberman, G Carlos Gomes, M A Kirschner.   

Abstract

BACKGROUND: The clinical features and natural history of adrenocortical carcinoma are highly dependent on the type of center reporting their experience. Observations from oncology services suggest a high incidence of nonfunctioning tumors, whereas reports from endocrine clinics emphasize excessive corticoid and androgen production in the majority of tumors. The incidence rate and natural history of childhood adrenal carcinoma generally has been under emphasized.
METHODS: Over the past 17 years, the authors have evaluated and treated 47 patients with adrenocortical carcinoma referred to the University of Sao Paulo, 22 of whom were children.
RESULTS: There is a bimodal age incidence of adrenal carcinoma, with the disease peaking in the first and fourth decades of life. Childhood adrenal carcinoma is characterized by a high rate of incidence of virilization, marked overproduction of androgens, and a less aggressive clinical course, and appears to be more amenable to surgical and other therapeutic modalities. By contrast, adrenocortical carcinoma occurring in adults presents more commonly as a mixed Cushing and virilizing syndrome, with overproduction of corticoids and androgens and a far more aggressive clinical course, leading to rapid death within months or years. Nonfunctioning adrenocortical carcinoma is less common; it generally occurs in older adults and exhibits a rapid downhill course. Modern day imaging methods have improved the diagnosis and staging of adrenal carcinoma greatly. In the authors' experience, the histologic criteria of Weiss appeared to predict tumor prognosis most accurately, whereas immunologic markers, cytoskeletal markers, DNA ploidy, cell phase markers, and oncogenic probes have yielded inconsistent results to date. Surgical removal of a localized tumor remains the best hope for long term survival. Medical therapy with mitotane and its successors in patients with Stage III or IV (MacFarlane system as modified by Sullivan et al.) disease appear to have added little to longevity or quality of life.
CONCLUSIONS: When diagnosed in children, adrenal carcinoma is associated with virilism and a less aggressive natural history; however, when it occurs in adults, the disease presents more commonly as a mixed Cushing-virilizing syndrome and has a virulent course. The Weiss histologic criteria appear to correlate best with disease prognosis, but other histochemical, cell cycle, and genetic markers have not, to date, aided in disease management. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10679640

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  104 in total

Review 1.  Management of adjuvant mitotane therapy following resection of adrenal cancer.

Authors:  M Terzolo; A Ardito; B Zaggia; F Laino; A Germano; S De Francia; F Daffara; A Berruti
Journal:  Endocrine       Date:  2012-06-17       Impact factor: 3.633

2.  An unusual cause of gynaecomastia.

Authors:  Sridhar Subbiah; Rama Walia; Santhosh Kumar; Uma Nahar; Anil Bhansali
Journal:  BMJ Case Rep       Date:  2011-07-20

3.  Giant adrenal pseudocyst harbouring adrenocortical cancer.

Authors:  Michael Wilkinson; Deirdre Mary Fanning; James Moloney; Hugh Flood
Journal:  BMJ Case Rep       Date:  2011-09-26

4.  Long-term outcome following laparoscopic adrenalectomy for large solid adrenal cortex tumors.

Authors:  F Fausto Palazzo; Frederic Sebag; Mauricio Sierra; Giuseppe Ippolito; Philippe Souteyrand; Jean-François Henry
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

5.  Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.

Authors:  Junna Ye; Yan Qi; Weiqing Wang; Fukang Sun; Qin Wei; Tingwei Su; Weiwei Zhou; Yiran Jiang; Wenqi Yuan; Jianfei Cai; Bin Cui; Guang Ning
Journal:  Endocrine       Date:  2012-02-04       Impact factor: 3.633

Review 6.  The molecular genetics of adrenocortical carcinoma.

Authors:  Ferdous M Barlaskar; Gary D Hammer
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

7.  Adrenocortical carcinoma with tumour thrombus extension to right atrium: a rare finding in uncommon tumour.

Authors:  Sachin Patil; Vishwajeet Singh; Amit Kumar; Satya Narayan Sankhwar
Journal:  BMJ Case Rep       Date:  2013-10-14

Review 8.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

9.  [Adrenal tumors: principles of imaging and differential diagnostics].

Authors:  C Degenhart
Journal:  Radiologe       Date:  2014-10       Impact factor: 0.635

10.  TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.

Authors:  Meenu Jain; Lisa Zhang; Mei He; Ya-Qin Zhang; Min Shen; Electron Kebebew
Journal:  Endocr Relat Cancer       Date:  2013-05-21       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.